phosphate metabolism modulation in chronic kidney disease: when, how and to what extent?

Authors

antonio bellasi division of nephrology, sant’ anna hospital, como, italy; department of health sciences, university of milan, italy; division of nephrology, sant’ anna hospital, como, italy, tel: +39-312073478, fax: +39-31.585.5762

biagio raffaele di iorio division of nephrology, a. landolfi hospital, solofra, italy

abstract

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

Phosphate Metabolism Modulation in Chronic Kidney Disease: When, How and to What Extent?

Implication for health policy/practice/research/medical education: The use of calcium containing vs. calcium free phosphate binder is one of the hot topic in Nephrology due to the survival benefit and cost burden associated with the use of the latter. Numerous observations have repeatedly shown that serum phosphorous is associated with poor survival (1). In a large cohort of 1,716 chronic kidne...

full text

Phosphate metabolism in chronic kidney disease: from pathophysiology to clinical management.

Hyperphosphatemia is considered as an independent risk factor for surrogate clinical endpoints like vascular calcification (VC) and bone disease, or hard clinical outcomes like cardiovascular events. To date, various treatment options for phosphate removal or reduction are available. The great expectations put into calcium-based phosphate binders were mitigated because of their possible contrib...

full text

Con: Phosphate binders in chronic kidney disease.

Phosphate binders are prescribed to chronic kidney disease (CKD) patients based on associations of serum phosphate concentrations with mortality and calcification, experimental evidence for direct calcifying effects of phosphate on vascular smooth muscle tissue and the central importance of phosphate retention in CKD-mineral and bone disorder (CKD-MBD). Current knowledge regarding phosphate met...

full text

Salivary phosphate secretion in chronic kidney disease.

BACKGROUND Hyperphosphatemia is an important contributor to cardiovascular calcification in chronic renal failure (CRF) patients. Cardiovascular calcifications are responsible for the high morbidity and mortality in patients undergoing hemodialysis (HD). Despite dietary phosphate reduction and treatment with phosphate binders, serum phosphorus level, as recommended by K/DOQI guidelines, is achi...

full text

My Resources

Save resource for easier access later


Journal title:
nephro-urology monthly

جلد ۶، شماره ۳، صفحات ۰-۰

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023